• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Dementia and Geriatric Cognitive Disorders Extra >Role of APOE and Age at Enrollment in the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT)
【24h】

Role of APOE and Age at Enrollment in the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT)

机译：APOE和入学年龄在阿尔茨海默氏病抗炎预防试验（ADAPT）中的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) tested whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent Alzheimer’s disease (AD). The results were null. We analyzed ADAPT data to examine if the effects of NSAIDs on AD risk differed depending upon APOE genotype or age as has been suggested by previous observational studies. Methods: ADAPT randomized 2,528 cognitively intact older adults to either celecoxib, naproxen sodium or placebo; 2,388 participants provided blood samples for APOE genotyping. Proportional hazards regression was used to estimate the effects of naproxen or celecoxib versus placebo on incident AD by age at enrollment and APOE genotype. Results: The proportion of subjects providing a biological sample did not differ between the treatment groups. In models of AD risk, none of the tests for 2-way interactions between either NSAID and age or APOE genotype were significant (p > 0.05). Conclusions: The data did not support the hypothesis that the association between NSAIDs and AD risk differed by age or APOE genotype.
机译：背景：阿尔茨海默氏病抗炎预防试验（ADAPT）测试了非甾体类抗炎药（NSAID）是否可以预防阿尔茨海默氏病（AD）。结果为空。我们分析了ADAPT数据，以检查NSAID对AD风险的影响是否因APOE基因型或年龄而异，如先前的观察研究所建议的那样。方法：ADAPT将2,528名认知完好的老年人随机分配给塞来昔布，萘普生钠或安慰剂。 2,388名参与者提供了用于APOE基因分型的血液样本。按入组年龄和APOE基因型，按比例风险回归评估萘普生或塞来昔布与安慰剂对比安慰剂对AD的影响。结果：提供生物学样品的受试者比例在各治疗组之间没有差异。在AD风险模型中，NSAID与年龄或APOE基因型之间的双向交互作用测试均无统计学意义（p> 0.05）。结论：数据不支持NSAID和AD风险之间的关联因年龄或APOE基因型而异的假设。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号